ORTHOFIX MEDICAL INC. Announces Leadership Realignment and Preliminary Q1 2026 Sales Results

Orthofix Medical Inc. has announced a strategic realignment of its Spine leadership team to accelerate growth and sharpen execution. Key Spine leaders will now report directly to the CEO, with expanded roles for Shaeffer Bannigan, Mark Sienkiewicz, and John Winge. Additionally, Patrick Fisher will lead the Biologics business. This restructuring aims to streamline decision-making and enhance commercial focus. The company also reported preliminary, unaudited net sales for the first quarter of 2026, totaling approximately $196.7 million, a 1.6% increase year-over-year. Pro forma net sales were approximately $196.4 million, up 3% on a constant currency basis, excluding M6 disc sales. Orthofix reaffirms its full-year 2026 guidance, expecting net sales between $850 million and $860 million, non-GAAP adjusted EBITDA of $95 million to $98 million, and positive free cash flow. The company also announced the departure of Max Reinhardt, President, Global Spine, effective June 12, 2026, which is expected to be treated under his change in control and severance agreement.